Earn up to 21.5 pharmacology contact hours* in person or virtually Thursday through Sunday.
|
Schedule is subject to change. APNA reserves the right to make program changes as necessary, and the right to cancel sessions if events occur beyond reasonable control of APNA.
*Includes Thursday Pre-Conference Add-on, which is an additional fee.
April Reyes, DNP, APRN, PMHNP-BC, FNP-BC, RH-CBS & Brittany Evans, DNP, APRN, PMHNP-BC
Review the 2021 coding guidelines, including the 2023 updates, along with pertinent add-on codes that can be used in mental health visits.
Brittany Evans, DNP, APRN, PMHNP-BC
Set the stage for the day of learning and how it connects to your nursing practice.
Timothy E. Wilens, MD
Examine the overlap of ADHD in patients with substance use disorders (SUD), as well as prevention and development of SUD. Review treatment strategies and recent data on the misuse of prescription stimulant medications.
Keynote: The Shocking Truth & Regulatory Implications of Job-Related Problems Associated with Suicide Among Healthcare ProfessionalsJudy E. Davidson, DNP, RN, MCCM, FAAN
Explore characteristics and antecedents of death by suicide among pharmacists, nurses, and physicians with a focus on job-related problems, including medication diversion and substance use. Understand regulatory implications, advocacy opportunities, and tested prevention strategies endorsed by the Surgeon General and Academy of Nurses.
Sponsored by Noven Pharmaceuticals
Lyons Hardy, MSN, PMHCNS, PMHNP
Focus on emerging theories in the conceptualization and pathophysiology of psychiatric disorders and explore 5 theoretical models. Within the biomedical model, primary themes will include inflammatory processes, microbiome imbalance, HPA axis alterations, and circadian rhythm disturbances.
Todd P. Levine, MD
Learn best practices to assess and document over time common behavior problems in children and adults with autism including insomnia, anxiety, irritability/aggression, and inattention/hyperactivity.
Barbara Limandri, PhD, PMHCNS-BC; Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN
Tie together the day’s learning and understand how it applies to your nursing practice.
Brittany Evans, DNP, APRN, PMHNP-BC
Set the stage for the day of learning and how it connects to your nursing practice.
Kristin Wason, MSN, NP-C, CARN
Discuss key updates on the evolving overdose epidemic, neurobiology of addiction, pharmacology of buprenorphine and its treatment goals, as well as buprenorphine maintenance and discontinuation.
Keynote: First Episode Psychosis: Looking Back to Look ForwardNina R. Schooler, PhD
Recognizing that patients’ first treatment experience has an important effect on longer term outcome, focus in on first episode psychosis (FEP). Examine antipsychotic medication treatment for FEP 1960-2020 through the lens of one researcher and get recommendations for future research and provision of treatment.
Sponsored by Alkermes
Capt. Joseph Holshoe, PMHNP-BC
Get updates on the new medications approved for Major Depressive Disorder (MDD) and how these new medications represent a shift in the understanding of the neurobiology of depression and mood disorders.
Mary Gutierrez, PharmD, BCPP
Optimize outcomes with pharmacogenomics: Gain an understanding of drug-gene interactions and how to personalize medications for your patients based on their genetic makeup.
Barbara Limandri, PhD, PMHCNS-BC; Barbara Jones Warren, PhD, RN, PMHCNS-BC, FNAP, FAAN
Tie together the day’s learning and understand how it applies to your nursing practice.
Rakesh Jain, MD, MPH
Understand how glutamate functions can negatively impact outcomes in psychiatric disorders. Learn new pharmacologic interventions and applications for daily clinical practice.
*This session will be presented virtually to in-person and virtual livestream attendees.
Maureen Cooney, DNP, FNP-BC, PMGT-BC, AP-PMN, ACHPN
Gain a deeper understanding of vital considerations for providing care to individuals who need psychiatric care who have co-existing pain conditions.
Dr. Josh Hamilton, APRN-BC, CTMH, CNE, CLNC, FAANP
Review updated diagnostic criteria and models of the bipolar spectrum to improve case identification, diagnosis & treatment. Redefine bipolar affective disorder in the context of epigenetics and neurobiology, focusing in on pharmacogenomics, contemporary pharmacological approaches, and practical applications for nurses.
Peter J. Weiden, MD
Understand the implications of knowing that direct dopamine receptor affinity is not always necessary for antipsychotic efficacy, and explore how to get ready for new therapies that might be available in the not-too-distant future.
Connect with fellow psychiatric-mental health nurses, be the first to know about evidence-based resources and programs, and participate in exclusive opportunities to advance the care and treatment of those with mental health & substance use needs.
